Skip to main content

Ticlid Side Effects

Generic name: ticlopidine

Medically reviewed by Last updated on Sep 8, 2022.

Note: This document contains side effect information about ticlopidine. Some of the dosage forms listed on this page may not apply to the brand name Ticlid.

For the Consumer

Applies to ticlopidine: oral tablets


  • Possible life-threatening adverse hematologic effects (e.g., neutropenia1 3 4 7 8 9 10 11 14 71 and/or agranulocytosis,1 7 9 10 20 71 thrombotic thrombocytopenic purpura [TTP],1 7 11 23 30 32 71 aplastic anemia1 7 16 17 20 22 24 25 26 27 71 ).

  • Neutropenia occurred in 2.4% of stroke patients in clinical trials;1 71 TTP and aplastic anemia reported rarely.1 71

  • Incidence of neutropenia, TTP, or aplastic anemia peaks about 4–6, 3–4, or 4–8 weeks, respectively, following initiation of therapy and declines thereafter.1 71 Adverse hematologic effects occur infrequently >3 months after initiation of therapy.1 71

  • Risk factors for development of adverse hematologic effects not identified.1 71

  • Careful clinical and hematologic monitoring required, especially during the first 3 months of therapy.1 4 11 71 Discontinue therapy immediately if adverse hematologic effects occur.1 71 (See Hematologic Toxicity under Cautions.)

Side effects include:

Diarrhea, nausea, dyspepsia, rash, GI pain, neutropenia, purpura, vomiting, flatulence, pruritus, dizziness, anorexia, abnormal liver function test.

For Healthcare Professionals

Applies to ticlopidine: oral tablet


The majority of cases of neutropenia, agranulocytosis, aplastic anemia, and thrombotic thrombocytopenic purpura occur during the first three months of treatment. US physicians reported 100 cases of TTP between 1992 and 1997. Delayed onset of neutropenia, after discontinuation of ticlopidine (the active ingredient contained in Ticlid) has been reported. Hematologic parameters should be monitored every other week for the first three months of therapy and ticlopidine should be discontinued if laboratory values are altered or if symptoms of infection or bleeding are noted. Thereafter, the patient should be monitored for signs of infection. Patients should be counseled concerning signs and symptoms of TTP (weakness, pallor, petechiae, purpura, dark urine, jaundice or mental status changes) and instructed to discontinue ticlopidine and immediately report any of these findings. Platelet infusions may accelerate thrombosis and should be avoided if possible.

Ecchymosis, epistaxis, hematuria, conjunctival hemorrhage, and gastrointestinal bleeding have been associated with ticlopidine therapy. Intracerebral bleeding occurred in approximately 0.5% of patients in clinical trials.

Postsurgical bleeding may also occur. To minimize the effects of postsurgical bleeding, it is generally recommended that ticlopidine be discontinued 2 weeks before any surgical or dental interventions.[Ref]

Hematologic dyscrasias have been the most serious adverse effects associated with ticlopidine therapy. Reversible neutropenia (severe in 0.9%) occurred in 2.4% of patients. Thrombocytopenia, agranulocytosis, pancytopenia, hemolytic anemia with reticulocytosis, and aplastic anemia have been reported.

Thrombotic thrombocytopenic purpura (TTP), not noted during clinical trials, has occurred at an estimated incidence of 1 case per 2000 to 4000 exposures. Symptoms include thrombocytopenia, microangiopathic hemolytic anemia (fragmented RBCs on a peripheral smear), renal dysfunction, fever, and neurological changes.[Ref]


Gastrointestinal disturbances have been noted in up to 40% of patients. Dyspepsia, nausea, diarrhea, vomiting, flatulence, and gastric pain have occurred. Some gastrointestinal symptoms lessen with continued therapy and administration with food may decrease gastrointestinal intolerance. Cases of ticlopidine-induced chronic diarrhea have been reported.[Ref]


Two case reports of patients developing maculopapular pruritic rashes following administration of clopidogrel have been reported. The rash recurred in both patients after switching to ticlopidine (the active ingredient contained in Ticlid) In one patient, rechallenge resulted in recurrence of the rash. These two cases illustrate the possibility of cross-sensitivity between thienopyridines.[Ref]

Dermatologic adverse effects have occurred frequently. Rash, generally maculopapular or urticarial, has been experienced in up to 15% of treated patients. At least one case of multiple fixed-drug eruptions, consisting of rash and generalized patches of hyperpigmentation, has been reported.[Ref]


Cholestatic jaundice has developed within 1 to 4 months of initiating therapy. Resolution of jaundice and normalization of hepatic enzymes concentrations occurred upon discontinuation of therapy.

Numerous cases of ticlopidine-induced cholestatic hepatitis have been reported. Time to the onset of hepatotoxicity is variable and ranges from 1 week to 6 months after initiating ticlopidine (the active ingredient contained in Ticlid) 2 to 12 weeks in most patients. In one patient, hepatotoxicity appeared 1 month after discontinuing ticlopidine because of rash. Symptoms and liver abnormalities resolved following discontinuation of ticlopidine, typically within 1 to 3 months; however, recovery time may be protracted (i.e. more than 12 months). Cases of irreversible hepatic damage have not been reported.[Ref]

Hepatic side effects typically have been mild and have included reversible elevations in liver function tests (up to 4%). The incidence of cholestatic jaundice has increased. Postmarketing side effects have included hepatitis and hepatic necrosis.[Ref]


Metabolic disturbances have included persistent elevation of total serum cholesterol.[Ref]


Reversible renal failure has been reported in patients receiving ticlopidine (the active ingredient contained in Ticlid) after stent implantation. Other postmarketing reports have included incidences of nephrotic syndrome.[Ref]


Side effects have occurred in up to 50% of patients. Generally, side effects have been mild and most frequently involved the gastrointestinal tract (30% to 40%). Diarrhea, rash, nausea, vomiting, gastric pain, and neutropenia were the primary cause of a 21% discontinuation rate. Asthenia and generalized pain have been reported.[Ref]

Nervous system

Nervous system side effects of dizziness, anorexia, and headache have been reported. Postmarketing reports of peripheral neuropathy have been noted.[Ref]


Postmarketing hypersensitivity reactions have included allergic pneumonitis, angioedema, vasculitis, and serum sickness. Several cases of ticlopidine-induced systemic and cutaneous lupus erythematosus (positive ANA) have been reported. Clinical improvement occurred in all patients following withdrawal of ticlopidine (the active ingredient contained in Ticlid) [Ref]


Postmarketing musculoskeletal side effects have included arthropathy and myositis. At least one case of ticlopidine-associated arthritis has been reported.[Ref]


1. Haynes RB, Sandler RS, Larson EB, Pater JL, Yatsu FM "A critical appraisal of ticlopidine, a new antiplatelet agent. Effectiveness and clinical indications for prophylaxis of atherosclerotic events." Arch Intern Med 152 (1992): 1376-80

2. Mataix R, Ojeda E, Perez MC, Jimenez S "Ticlopidine and severe aplastic anaemia." Br J Haematol 80 (1992): 125-6

3. Troussard X, Mayo P, Mosquet B, Reman O, Leporrier M "Ticlopidine and severe aplastic anaemia ." Br J Haematol 82 (1992): 779-80

4. Garnier G, Taillan B, Pesce A, Chichmanian RM, Dujardin P "Ticlopidine and severe aplastic anaemia." Br J Haematol 81 (1992): 459-60

5. Janzon L, Bergqvist D, Boberg J, Boberg M, Eriksson I, Lindgarde F, Persson G, Almgren B, Fagher B, Kjellstrom T, et al. "Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study [published erratum appears in J Intern Med 1990 Dec;228(6):659]." J Intern Med 227 (1990): 301-8

6. Page Y, Tardy B, Zeni F, Comtet C, Terrana R, Bertrand JC "Thrombotic thrombocytopenic purpura related to ticlopidine." Lancet 337 (1991): 774-6

7. "Ticlopidine for prevention of stroke." Med Lett Drugs Ther 34 (1992): 65-6

8. Hass WK, Easton JD, Adams HP, Jr Pryse-Phillips W, Molony BA, Anderson S, Kamm B "A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group." N Engl J Med 321 (1989): 501-7

9. Weisberg LA "The efficacy and safety of ticlopidine and aspirin in non-whites: analysis of a patient subgroup from the Ticlopidine Aspirin Stroke Study." Neurology 43 (1993): 27-31

10. Ellie E, Durrieu C, Besse P, Julien J, Gbipki-Benissan G "Thrombotic thrombocytopenic purpura associated with ticlopidine ." Stroke 23 (1992): 922-3

11. Ono K, Kurohara K, Yoshihara M, Shimamoto Y, Yamaguchi M "Agranulocytosis caused by ticlopidine and its mechanism." Am J Hematol 37 (1991): 239-42

12. Saltiel E, Ward A "Ticlopidine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in platelet-dependent disease states." Drugs 34 (1987): 222-62

13. McTavish D, Faulds D, Goa KL "Ticlopidine. An updated review of its pharmacology and therapeutic use in platelet-dependent disorders [published erratum appears in Drugs 1990 Oct;40(4):following Table of Contents]." Drugs 40 (1990): 238-59

14. "Product Information. Ticlid (ticlopidine)." Syntex Laboratories Inc (2001):

15. Khelif A, Assouline D, Ffrench M, Chaumentin G, Viala JJ "Ticlopidine and aplastic anaemia." Br J Haematol 83 (1993): 678-9

16. Martinnunez G, Fdezsoria RR, Sanchezgil F, Benitezcano E "Aplastic anaemia and ticlopidine." Br J Haematol 85 (1993): 633

17. Desager JP "Clinical pharmacokinetics of ticlopidine." Clin Pharmacokinet 26 (1994): 347-55

18. Mallet L, Mallet J "Ticlopidine and fatal anemia in an elderly woman." Ann Pharmacother 28 (1994): 1169-71

19. Lesesve JF, Callat MP, Lenormand B, Monconduit M, Noblet C, Moore N, Caron F, Humbert G, Stamatoullas A, Tilly H "Hematological toxicity of ticlopidine." Am J Hematol 47 (1994): 149-50

20. Carlson JA, Maesner JE "Fatal neutropenia and thrombocytopenia associated with ticlopidine." Ann Pharmacother 28 (1994): 1236-8

21. Farver DK, Hansen LA "Delayed neutropenia with ticlopidine." Ann Pharmacother 28 (1994): 1344-6

22. Weiner P, Paz R, Zidan F "Severe aplastic anemia due to ticlopidine." Isr J Med Sci 31 (1995): 444-5

23. Arribalzaga K, Garciasuarez J, Lopezrubio M, Krsnik I, Calero MA, Delcampo JF "Sustained granulocyte recovery after g-CSF in a patient with ticlopidine-induced severe aplastic anemia." Am J Hematol 50 (1995): 313

24. Dunn P "Aplastic anemia with ticlopidine therapy in two Chinese patients." Ann Pharmacother 30 (1996): 547

25. Kupfer Y, Tessler S "Ticlopidine and thrombotic thrombocytopenia purpura." N Engl J Med 337 (1997): 1245

26. Ochoa AB, Wolfe M, Lewis P, Lenihan DJ "Ticlopidine-induced neutropenia mimicking sepsis early after intracoronary stent placement." Clin Cardiol 21 (1998): 304-7

27. Ferrer F, DeArriba F, Moraleda JM, Vicente V "Aplastic anaemia induced by ticlopidine after placement of coronary artery stents: Therapeutic role of granulocyte colony-stimulating factor." Clin Drug Invest 15 (1998): 261-2

28. Bennett CL, Weinberg PD, Rozenberg-Ben-Dror K, Yarnold PR, Kwaan HC, Green D "Thrombotic thrombocytopenic purpura associated with ticlopidine." Ann Intern Med 128 (1998): 541-4

29. Ceylan C, Kirimli O, Akarsu M, Undar B, Guneri S "Early ticlopidine-induced hepatic dysfunction, dermatitis and irreversible aplastic anemia after coronary artery stenting." Am J Hematol 59 (1998): 260

30. Muszkat M, Shapira MY, Sviri S, Linton DM, Caraco Y "Ticlopidine-induced thrombotic thrombocytopenic purpura." Pharmacotherapy 18 (1998): 1352-5

31. Chen DK, Kim JS, Sutton DMC "Thrombotic thrombocytopenic purpura associated with ticlopidine use - A report of 3 cases and review of the literature." Arch Intern Med 159 (1999): 311-4

32. Steinhubl SR, Tan WA, Foody JM, Topol EJ "Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting." JAMA 281 (1999): 806-10

33. Mukamal KJ, Wu B "Ticlopidine-associated thrombotic thrombocytopenic purpura." Ann Intern Med 129 (1998): 837

34. Quinn MW, Dillard TA "Delayed traumatic hemothorax on ticlopidine and aspirin for coronary stent." Chest 116 (1999): 257-60

35. Elangovan L "Thrombotic thrombocytopenic purpura associated with ticlopidine use." Arch Intern Med 159 (1999): 1624

36. Dunlop H "Serious hematologic reactions associated with ticlopidine - update." Can Med Assn J 161 (1999): 867-8

37. Quinn MJ, Fitzgerald DJ "Ticlopidine and clopidogrel." Circulation 100 (1999): 1667-72

38. Bennett CL, Davidson CJ, Green D, Weinberg PD, Feldman MD "Ticlopidine and TTP coronary stenting." JAMA 282 (1999): 1717

39. Bennett CL, Davidson CJ, Raisch DW, Weinberg PD, Bennett RH, Feldman MD "Thrombotic thrombocytopenic purpura associated with ticlopidine in the setting of coronary artery stents and stroke prevention." Arch Intern Med 159 (1999): 2524-8

40. ParadisoHardy FL, Angelo CM, Lanctot KL, Cohen EA "Hematologic dyscrasia associated with ticlopidine therapy: evidence for causality." Can Med Assn J 163 (2000): 1441-8

41. Rimbrot S, Kundzinsh E, Levy Y "Invasive aspergillosis in a patient with ticlopidine-induced agranulocytosis." Arch Intern Med 160 (2000): 3498-9

42. Fraga M, Garcia B, Agud JL, Marco J, de Juana P, Cervero M "Severe chronic diarrhea induced by ticlopidine." Ann Pharmacother 30 (1996): 1496

43. Mansoor GA, Aziz K "Delayed chronic diarrhea and weight loss possibly due to ticlopidine therapy." Ann Pharmacother 31 (1997): 870-2

44. Bequemin JP "Effect of ticlopidine on the long-term patency of saphenous-vein bypass grafts in the legs." N Engl J Med 337 (1997): 1726-31

45. Berrebi D, Sautet A, Flejou JF, Dauge MC, Peuchmaur M, Potet F "Ticlopidine induced colitis: a histopathological study including apoptosis." J Clin Pathol 51 (1998): 280-3

46. Berger PB, Bell MR, Hasdai D, Grill DE, Melby S, Holmes DR "Safety and efficacy of ticlopidine for only 2 weeks after successful intracoronary stent placement." Circulation 99 (1999): 248-53

47. Borras-Blasco J, Navarro-Ruiz A, Gutierrez-Casbas A, Matarredona-Catala J, Gonzalez-Delgado M "Multiple fixed-drug eruption and diarrhea with ticlopidine." Ann Pharmacother 36 (2002): 344-5

48. Wall GC, Heyneman CA "Calcitonin in phantom limb pain." Ann Pharmacother 33 (1999): 499-501

49. Hsi DH, Mock DT, Rocco TA "Toxic erythroderma due to ticlopidine." N Engl J Med 340 (1999): 1212

50. Yosipovitch G, Rechavia E, Feinmesser M, David M "Adverse cutaneous reactions to ticlopidine in patients with coronary stents." J Am Acad Dermatol 41 (1999): 473-6

51. Cannavo SP, Borgia F, Guarneri F, Vaccaro M "Acute generalized exanthematous pustulosis following use of ticlopidine." Br J Dermatol 142 (2000): 577-8

52. Makkar K, Wilensky RL, Julien MB, Herrmann HC, Spinler SA "Rash with both clopidogrel and ticlopidine in two patients following percutaneous coronary intervention with drug-eluting stents." Ann Pharmacother 40 (2006): 1204-7

53. Greany JJ, Jr Hess DA, Mahoney CD "Ticlopidine-induced cholestatic jaundice." Clin Pharm 12 (1993): 398-9

54. Yoder JD, Algozzine GJ, Hill GW "More ticlopidine-induced cholestatic jaundice." Am J Hosp Pharm 51 (1994): 1821-2

55. Colivicchi F, Magnanimi S, Sebastiani F, Silvestri R, Magnanimi R "Ticlopidine-induced chronic cholestatic hepatitis: a case report." Curr Ther Res Clin Exp 55 (1994): 929-31

56. Cassidy LJ, Schuster BG, Halparin LS "Probable ticlopidine-induced cholestatic hepatitis." Ann Pharmacother 29 (1995): 30-2

57. Ruiz-Valverde P, Zafon C, Segarra A, Ribera R, Piera L "Ticlopidine-induced granulomatous hepatitis." Ann Pharmacother 29 (1995): 633-4

58. Klepser TB, Jogerst GJ "Ticlopidine-induced elevated liver enzymes." Pharmacotherapy 17 (1997): 819-21

59. Iqbal M, Goenka P, Young MF, Thomas E, Borthwick TR "Ticlopidine-induced cholestatic hepatitis: Report of three cases and review of the literature." Dig Dis Sci 43 (1998): 2223-6

60. PerezBalsa AM, DeArce A, Castiella A, Lopez P, Ruibal M, RuizMartinez J, DeMunain AL, Masso JFM "Hepatotoxicity due to ticlopidine." Ann Pharmacother 32 (1998): 1250-1

61. Goff JS "Lansoprazole: A cause of secretory diarrhea." Am J Gastroenterol 93 (1998): 2298-9

62. Kubin CJ, Sherman O, Hussain KB, Feinman L "Delayed-onset ticlopidine-induced cholestatic jaundice." Pharmacotherapy 19 (1999): 1006-10

63. Wengrower D "Possible ticlopidine-induced cholestatic jaundice." Am Fam Physician 62 (2000): 1258+

64. Skurnik YD, Tcherniak A, Edlan K, Sthoeger Z "Ticlopidine-induced cholestatic hepatitis." Ann Pharmacother 37 (2003): 371-5

65. Naschitz JE, Khamessi R, Elias N, Yeshurun D "Ticlopidine-induced prolonged cholestasis." J Toxicol Clin Toxicol 33 (1995): 379-80

66. Azar R, Boldron A, Bakhache E, Elazouzi A "Ticlopidine and renal function." Lancet 348 (1996): 1031

67. Zijlstra F, Elsman P "Ticlopidine and renal function - reply." Lancet 348 (1996): 1031

68. Virdee M, Collinson J, Stables RH "Ticlopidine and renal function." Lancet 348 (1996): 1031-2

69. Persoz CF, Cornella F, Kaeser P, Rochat T "Ticlopidine-induced interstitial pulmonary disease - A case report." Chest 119 (2001): 1963-5

70. Persoz CF, Cornella F, Kaeser P, Rochat T "Ticlopidine-induced interstitial pulmonary disease - A case report." Chest 119 (2001): 1963-5

71. Spiera RF, Berman RS, Werner AJ, Spiera H "Ticlopidine-induced lupus: a report of 4 cases." Arch Intern Med 162 (2002): 2240-3

72. Reich A, Bialynicki-Birula R, Szepietowski JC "Drug-induced subacute cutaneous lupus erythematosus resulting from ticlopidine." Int J Dermatol 45 (2006): 1112-4

73. Dakik HA, Salti I, Haidar R, Uthman IW "Ticlopidine associated with acute arthritis." BMJ 324 (2002): 27

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.